A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

February 18, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
Parkinson Disease
Interventions
DRUG

LY4006896

Administered intravenously (IV)

DRUG

Placebo

Administered IV

Trial Locations (13)

32127

NOT_YET_RECRUITING

Progressive Medical Research, Port Orange

32159

NOT_YET_RECRUITING

K2 Medical Research, LLC, The Villages

32751

NOT_YET_RECRUITING

K2 Medical Research, LLC, Maitland

32803

NOT_YET_RECRUITING

Charter Research, Orlando

34105

NOT_YET_RECRUITING

Aqualane Clinical Research, Naples

48334

NOT_YET_RECRUITING

QUEST Research Institute, Farmington Hills

78744

RECRUITING

PPD Development, LP, Austin

90720

NOT_YET_RECRUITING

Collaborative Neuroscience Network - CNS, Los Alamitos

NOT_YET_RECRUITING

Collaborative Neuroscience Network - CNS, Los Alamitos

98034

NOT_YET_RECRUITING

Evergreen Health Research, Kirkland

32162-2698

NOT_YET_RECRUITING

Charter Research, The Villages

192-0071

NOT_YET_RECRUITING

P-One Clinic, Hachiōji

879-5593

NOT_YET_RECRUITING

Oita University Hospital, Yufu

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY